Sign in
ETNB Stock Price, Chart, Stats & News
89bio, Inc.
Save
2.20B
Market cap
–
Current P/E
–
Forward P/E
ETNB chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -123.81% |
Operating margin | -2217504.76% |
Pretax margin | -2137404.76% |
Net margin | -2143838.10% |
Effective tax rate | -0.30% |
ROA | -74.60% |
ROE | -94.48% |
D/E | 0.07x |
Interest coverage ratio | -78.17x |
ETNB valuation
P/E | – |
P/S | 104798.07x |
P/B | 4.49x |
P/CF | -5.34x |
P/FCF | -5.01x |
P/OCF | -5.34x |
PEG | 0.76x |
EV multiple | -5.11x |
About
Operating as a clinical-stage biopharmaceutical company, 89bio, Inc. is dedicated to advancing and commercializing therapeutic solutions for ailments impacting the liver and metabolic system. Their flagship product candidate, pegozafermin, is a modified fibroblast growth factor 21 (FGF21) analog specifically designed to address nonalcoholic steatohepatitis (NASH). Furthermore, the company has plans to explore pegozafermin's utility in treating severe hypertriglyceridemia.
Similar securities
Based on sector and market capitalization
Report issue